febuxostat造句

• Febuxostat was discovered by scientists at the Japanese pharmaceutical company Teijin in 1998.
• Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese authorities in 2011.
• Ipsen obtained marketing approval for febuxostat from the European Medicines Agency in April 2008, Takeda obtained FDA approval in February 2009, and Teijin obtained approval from the Japanese " Pharmaceuticals and Medical Devices Agency " in 2011.
• It is treatable with regular doses of allopurinol or febuxostat, which inhibit xanthine dehydrogenase activity to prevent the accumulation and precipitation of DHA . The condition can also be attenuated with a low-purine diet and high fluid intake.
• Xanthine oxidase inhibitors ( including allopurinol and febuxostat ) block uric acid production, and long-term therapy is safe and well tolerated, and can be used in people with decreased kidney function or urate stones, although allopurinol has caused hypersensitivity in a small number of individuals.
• When uric acid levels and gout symptoms cannot be controlled with standard gout medicines that decrease the production of uric acid ( e . g ., allopurinol, febuxostat ) or increase uric acid elimination from the body through the kidneys ( e . g ., probenecid ), this can be referred to as refractory chronic gout ( RCG ).